Diorio et al demonstrate that base editing enabled higher cell viability, better proliferation, and optimized CAR T-cell yields when compared with the conventional CRISPR-Cas9 nuclease system. This may be explained by reduced DNA damage response observed after quadruple editing with CBEs and better cellular fitness in the absence of gross genetic rearrangements. With overall yields between 16 × 109and 17.2 × 109 CAR+ T cells, a single manufacturing run may provide up to 200 administrations in adult patients (assuming a treatment dose of 1 × 106 CAR+ T cells per kilogram of body
https://ashpublications.org/blood/article/140/6/526/486105/The-uncut-version-base-edited-allo-CAR-T-cells
https://ashpublications.org/blood/article/140/6/526/486105/The-uncut-version-base-edited-allo-CAR-T-cells
Recent FATE News
- Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (Canada) • 05/29/2026 01:00:00 PM
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (US) • 05/29/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:02:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:01:08 PM
- Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases • GlobeNewswire Inc. • 05/21/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 07:41:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 07:38:54 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (Canada) • 05/19/2026 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 12:34:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 12:32:07 PM
- Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:00:36 PM
- Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 • GlobeNewswire Inc. • 05/05/2026 12:30:00 PM
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases • GlobeNewswire Inc. • 05/04/2026 01:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/01/2026 08:05:00 PM
- Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting • GlobeNewswire Inc. • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 08:09:40 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:08:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:03:55 PM
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annua • GlobeNewswire Inc. • 04/16/2026 01:00:00 PM
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences • GlobeNewswire Inc. • 04/09/2026 01:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
